Area of research
Immunology · Biotechnology
Research interest
Research interests include Toxin Mechanisms and Immunotoxins, Transgenic Plants and Applications, Monoclonal and Polyclonal Antibodies Research, and CAR-T cell therapy research.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.
Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.
Response to Pegylated Interferon in a COVID-19 Positive Male with Metastatic Jejunal Neuroendocrine Tumor Treated with Everolimus
Response to Pegylated Interferon in a COVID-19 Positive Elderly Woman with Primary Myelofibrosis Treated with Ruxolitinib
Roles of the cGAS-STING Pathway in Cancer Immunosurveillance and Immunotherapy
The Prevalence of DPYD*9A (c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
A STING-activating nanovaccine for cancer immunotherapy
Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037
Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients
Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies
Arginine deprivation therapy for malignant melanoma